KYMR - Kymera Therapeutics

-

$undefined

N/A

(N/A)

Kymera Therapeutics NasdaqGM:KYMR Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Location: 500 North Beacon Street, Suite 230, Watertown, MA, 02472, United States | Website: https://www.kymeratx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.593B

Cash

463.2M

Avg Qtr Burn

-58.52M

Short % of Float

16.79%

Insider Ownership

2.69%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Initiation

KT-474 Details
Hidradenitis suppurativa, Rheumatoid arthritis, Atopic dermatitis

Phase 2

Data readout

KT-621 Details
Atopic dermatitis

Phase 1

Data readout

KT-294 Details
Inflammatory disease, Autoimmune disease

Phase 1

Data readout

KT-621 Details
Inflammatory disease, Allergy

Phase 1

Data readout

KT-579 Details
Inflammatory disorders

Phase 1

Initiation

KT-333 Details
Solid tumor/s, Cancer

Failed

Discontinued

KT-295 Details
Inflammatory bowel disease, Psoriasis

Failed

Discontinued

KT-253 Details
Solid tumor/s, Cancer, Acute myeloid leukemia, Lymphoma

Failed

Discontinued

KT-413 Details
Solid tumor/s, Cancer

Failed

Discontinued